Dr. Reddy’s Laboratories Ltd (DRL) has announced that it has launched Tetrabenazine Tablets, a therapeutic equivalent generic version of Xenazine (tetrabenazine) in the United States market approved by the U.S. Food and Drug Administration (USFDA). The Xenazine brand and generic had U.S. sales of approximately $322 million MAT for the most recent twelve months ending in November 2017 according to IMS Health*. Dr. Reddy’s Tetrabenazine Tablets are available in strengths of 12.5 mg and 25 mg, each strength is available in a bottle count size of 112. Xenazine is a registered trademark of Valeant Pharmaceuticals Luxembourg S.A.R.L.
The drug, which is used to treat and monitor patients for the emergence or worsening of depression, suicidality, or unusual changes in behavior, was approved by the US Food and Drug Administration (USFDA), DRL said in the statement. DRL said the Xenazine brand and generic had U.S. sales of approximately $322 million MAT for the twelve months ending November 2017.